Skip to main content
hello world

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

Newswire.ca - Tue Nov 7, 2023

MONTREAL and CHARLOTTE, N.C., Nov. 7, 2023 /CNW/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that the Company will host a virtual investor and analyst webcast on Monday, November 13, 2023 at 8:00 a.m. ET. The webcast will focus on results from the ReVeRA Phase 2 study of investigational new drug etripamil in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR), which is being presented as a Featured Science presentation at the American Heart Association (AHA) Scientific Sessions 2023.  

Read more at newswire.ca